We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
+28.03%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$955M
AUM Growth
+$52.9M
Cap. Flow
-$132M
Cap. Flow %
-13.83%
Top 10 Hldgs %
81%
Holding
26
New
2
Increased
5
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
DVAX
Dynavax Technologies
DVAX
+$35.5M
2
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$19.7M
3
COGT icon
Cogent Biosciences
COGT
+$16.4M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$10.8M
5
TYRA icon
Tyra Biosciences
TYRA
+$2.87M

Top Sells

Rank Stock Value
1
VERA icon
Vera Therapeutics
VERA
+$75.7M
2
IMGN
Immunogen Inc
IMGN
+$42.2M
3
MOR
MorphoSys AG American Depositary Shares
MOR
+$41.9M
4
NTRA icon
Natera
NTRA
+$30.1M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$23.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMGN
26
DELISTED
Immunogen Inc
IMGN
– –
-1,422,503
Closed -$42.2M
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Kynam Capital Management held 26 positions worth $955M, up 5.9% from $903M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Kynam Capital Management withdrew a net $132M in Q1 2024, closing 3 positions and reducing 8 holdings. Its most notable exit was Immunogen Inc, an estimated $42.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 98% a quarter earlier.

Against the trend, Kynam Capital Management opened a new position in Ironwood Pharmaceuticals worth $14.2M.

  • Kynam Capital Management's largest Q1 2024 buy was Ironwood Pharmaceuticals: 1,625,000 shares worth $14.2M.
  • Kynam Capital Management added most to Dynavax Technologies in Q1 2024, an estimated $35.5M increase.
  • Kynam Capital Management's biggest Q1 2024 reduction was Vera Therapeutics, cutting an estimated $75.7M.
  • Kynam Capital Management fully exited Immunogen Inc in Q1 2024, selling an estimated $42.2M.
  • Kynam Capital Management's ten largest holdings make up 81% of its $955M portfolio in Q1 2024.
  • Kynam Capital Management opened 2 new positions and closed 3 in Q1 2024.
  • Kynam Capital Management's portfolio value rose 5.9% quarter-over-quarter to $955M.

Based on Kynam Capital Management's 13F filing for Q1 2024, filed 15 May 2024.